Nutra Pharma Corp Stock Performance
| NPHC Stock | USD 0.0001 0.00 0.00% |
Nutra Pharma holds a performance score of 6 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of -18.0, which conveys a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Nutra Pharma are expected to decrease by larger amounts. On the other hand, during market turmoil, Nutra Pharma is expected to outperform it. Use Nutra Pharma Corp maximum drawdown and the relationship between the downside variance and day median price , to analyze future returns on Nutra Pharma Corp.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Nutra Pharma Corp are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of rather conflicting technical indicators, Nutra Pharma exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Nutra |
Nutra Pharma Relative Risk vs. Return Landscape
If you would invest 0.06 in Nutra Pharma Corp on December 5, 2025 and sell it today you would lose (0.05) from holding Nutra Pharma Corp or give up 83.33% of portfolio value over 90 days. Nutra Pharma Corp is currently generating 3.8506% in daily expected returns and assumes 48.9718% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Nutra, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Nutra Pharma Target Price Odds to finish over Current Price
The tendency of Nutra Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.0001 | 90 days | 0.0001 | about 69.54 |
Based on a normal probability distribution, the odds of Nutra Pharma to move above the current price in 90 days from now is about 69.54 (This Nutra Pharma Corp probability density function shows the probability of Nutra Pink Sheet to fall within a particular range of prices over 90 days) .
Nutra Pharma Price Density |
| Price |
Predictive Modules for Nutra Pharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Nutra Pharma Corp. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Nutra Pharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Nutra Pharma is not an exception. The market had few large corrections towards the Nutra Pharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Nutra Pharma Corp, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Nutra Pharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 7.20 | |
β | Beta against Dow Jones | -18 | |
σ | Overall volatility | 0.0002 | |
Ir | Information ratio | 0.16 |
Nutra Pharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Nutra Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Nutra Pharma Corp can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Nutra Pharma Corp is way too risky over 90 days horizon | |
| Nutra Pharma Corp has some characteristics of a very speculative penny stock | |
| Nutra Pharma Corp appears to be risky and price may revert if volatility continues | |
| Nutra Pharma Corp has high likelihood to experience some financial distress in the next 2 years | |
| Nutra Pharma Corp currently holds 517.18 K in liabilities. Nutra Pharma Corp has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Nutra Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Nutra Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Nutra Pharma Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Nutra to invest in growth at high rates of return. When we think about Nutra Pharma's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 51.9 K. Net Loss for the year was (769.18 K) with profit before overhead, payroll, taxes, and interest of 8.47 K. | |
| Nutra Pharma Corp currently holds about 10.45 K in cash with (878.09 K) of positive cash flow from operations. | |
| Latest headline from MacroaxisInsider: Discretionary transaction by Perri Rose C of tradable shares of Eastgate Biotech subject to Rule 16b-3 |
Nutra Pharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Nutra Pink Sheet often depends not only on the future outlook of the current and potential Nutra Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Nutra Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 6.6 B | |
| Cash And Short Term Investments | 90.9 K |
Nutra Pharma Fundamentals Growth
Nutra Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Nutra Pharma, and Nutra Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Nutra Pink Sheet performance.
| Return On Asset | -1.13 | |||
| Profit Margin | 28.71 % | |||
| Operating Margin | (5.58) % | |||
| Current Valuation | 10.33 M | |||
| Shares Outstanding | 7.6 B | |||
| Price To Sales | 6.13 X | |||
| Revenue | 51.9 K | |||
| EBITDA | (365.66 K) | |||
| Cash And Equivalents | 10.45 K | |||
| Total Debt | 517.18 K | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (878.09 K) | |||
| Total Asset | 301.79 K | |||
About Nutra Pharma Performance
By analyzing Nutra Pharma's fundamental ratios, stakeholders can gain valuable insights into Nutra Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Nutra Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Nutra Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company was incorporated in 2000 and is based in Plantation, Florida. NUTRA PHARMA operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 4 people.Things to note about Nutra Pharma Corp performance evaluation
Checking the ongoing alerts about Nutra Pharma for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Nutra Pharma Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Nutra Pharma Corp is way too risky over 90 days horizon | |
| Nutra Pharma Corp has some characteristics of a very speculative penny stock | |
| Nutra Pharma Corp appears to be risky and price may revert if volatility continues | |
| Nutra Pharma Corp has high likelihood to experience some financial distress in the next 2 years | |
| Nutra Pharma Corp currently holds 517.18 K in liabilities. Nutra Pharma Corp has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Nutra Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Nutra Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Nutra Pharma Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Nutra to invest in growth at high rates of return. When we think about Nutra Pharma's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 51.9 K. Net Loss for the year was (769.18 K) with profit before overhead, payroll, taxes, and interest of 8.47 K. | |
| Nutra Pharma Corp currently holds about 10.45 K in cash with (878.09 K) of positive cash flow from operations. | |
| Latest headline from MacroaxisInsider: Discretionary transaction by Perri Rose C of tradable shares of Eastgate Biotech subject to Rule 16b-3 |
- Analyzing Nutra Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nutra Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Nutra Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Nutra Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nutra Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Nutra Pharma's pink sheet. These opinions can provide insight into Nutra Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Nutra Pink Sheet analysis
When running Nutra Pharma's price analysis, check to measure Nutra Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nutra Pharma is operating at the current time. Most of Nutra Pharma's value examination focuses on studying past and present price action to predict the probability of Nutra Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nutra Pharma's price. Additionally, you may evaluate how the addition of Nutra Pharma to your portfolios can decrease your overall portfolio volatility.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |